Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.32
IDXX's Cash-to-Debt is ranked lower than
80% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. IDXX: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
IDXX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 11.61 Max: No Debt
Current: 0.32
Equity-to-Asset -0.05
IDXX's Equity-to-Asset is ranked lower than
93% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. IDXX: -0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
IDXX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07  Med: 0.78 Max: 0.9
Current: -0.05
-0.07
0.9
Debt-to-Equity -15.11
IDXX's Debt-to-Equity is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. IDXX: -15.11 )
Ranked among companies with meaningful Debt-to-Equity only.
IDXX' s Debt-to-Equity Range Over the Past 10 Years
Min: -133.82  Med: 0.03 Max: 129.54
Current: -15.11
-133.82
129.54
Debt-to-EBITDA 2.76
IDXX's Debt-to-EBITDA is ranked lower than
63% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. IDXX: 2.76 )
Ranked among companies with meaningful Debt-to-EBITDA only.
IDXX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.44  Med: 0.78 Max: 3.15
Current: 2.76
0.44
3.15
Interest Coverage 11.63
IDXX's Interest Coverage is ranked lower than
62% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. IDXX: 11.63 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 10.26  Med: 43.56 Max: 91.84
Current: 11.63
10.26
91.84
Piotroski F-Score: 8
Altman Z-Score: 7.32
Beneish M-Score: -2.59
WACC vs ROIC
4.62%
37.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 20.79
IDXX's Operating Margin % is ranked higher than
92% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IDXX: 20.79 )
Ranked among companies with meaningful Operating Margin % only.
IDXX' s Operating Margin % Range Over the Past 10 Years
Min: 14.76  Med: 18.6 Max: 20.79
Current: 20.79
14.76
20.79
Net Margin % 14.13
IDXX's Net Margin % is ranked higher than
89% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. IDXX: 14.13 )
Ranked among companies with meaningful Net Margin % only.
IDXX' s Net Margin % Range Over the Past 10 Years
Min: 10.19  Med: 12.38 Max: 14.13
Current: 14.13
10.19
14.13
ROA % 17.03
IDXX's ROA % is ranked higher than
95% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. IDXX: 17.03 )
Ranked among companies with meaningful ROA % only.
IDXX' s ROA % Range Over the Past 10 Years
Min: 13.44  Med: 15.68 Max: 17.03
Current: 17.03
13.44
17.03
ROC (Joel Greenblatt) % 73.20
IDXX's ROC (Joel Greenblatt) % is ranked higher than
92% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. IDXX: 73.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IDXX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.83  Med: 62.77 Max: 73.2
Current: 73.2
53.83
73.2
3-Year Revenue Growth Rate 15.30
IDXX's 3-Year Revenue Growth Rate is ranked higher than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. IDXX: 15.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IDXX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.4  Med: 14.1 Max: 35.6
Current: 15.3
8.4
35.6
3-Year EBITDA Growth Rate 16.70
IDXX's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. IDXX: 16.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IDXX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.5  Med: 15.1 Max: 96.9
Current: 16.7
-31.5
96.9
3-Year EPS without NRI Growth Rate 11.90
IDXX's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. IDXX: 11.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IDXX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -0.5  Med: 16.4 Max: 50.4
Current: 11.9
-0.5
50.4
GuruFocus has detected 3 Warning Signs with IDEXX Laboratories Inc IDXX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IDXX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

IDXX Guru Trades in Q3 2016

Jim Simons 694,304 sh (+29.20%)
Mairs and Power 3,998 sh (unchged)
Ruane Cunniff 106,944 sh (-0.88%)
Ron Baron 6,500,206 sh (-1.29%)
Chuck Royce 708,990 sh (-17.92%)
Paul Tudor Jones 4,599 sh (-19.49%)
Columbia Wanger 224,612 sh (-39.37%)
» More
Q4 2016

IDXX Guru Trades in Q4 2016

Mairs and Power 3,998 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 613,200 sh (-11.68%)
Ron Baron 5,690,887 sh (-12.45%)
Columbia Wanger 183,232 sh (-18.42%)
Chuck Royce 382,900 sh (-45.99%)
Ruane Cunniff 27,741 sh (-74.06%)
» More
Q1 2017

IDXX Guru Trades in Q1 2017

Jim Simons 975,600 sh (+59.10%)
Mairs and Power 4,598 sh (+15.01%)
Columbia Wanger 164,261 sh (-10.35%)
Ron Baron 5,069,276 sh (-10.92%)
Ruane Cunniff 24,618 sh (-11.26%)
Chuck Royce 316,300 sh (-17.39%)
» More
Q2 2017

IDXX Guru Trades in Q2 2017

Caxton Associates 2,600 sh (New)
Lee Ainslie 23,580 sh (New)
Jim Simons 1,351,900 sh (+38.57%)
Chuck Royce 316,300 sh (unchged)
Mairs and Power 4,598 sh (unchged)
Ron Baron 4,726,336 sh (-6.77%)
Columbia Wanger 116,083 sh (-29.33%)
Ruane Cunniff 3,365 sh (-86.33%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Reduce -6.77%0.28%$153.6 - $171.94 $ 163.050%4,726,336
Ruane Cunniff 2017-06-30 Reduce -86.33%0.03%$153.6 - $171.94 $ 163.050%3,365
Ron Baron 2017-03-31 Reduce -10.92%0.41%$115.95 - $154.72 $ 163.0518%5,069,276
Ruane Cunniff 2017-03-31 Reduce -11.26%$115.95 - $154.72 $ 163.0518%24,618
Ron Baron 2016-12-31 Reduce -12.45%0.5%Premium Member Access $117.27 $ 163.0539%5,690,887
Ron Baron 2016-12-31 Reduce -12.45%0.48%$103.98 - $120.83 $ 163.0543%5,690,887
Ruane Cunniff 2016-12-31 Reduce -74.06%0.08%$103.98 - $120.83 $ 163.0543%27,741
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2835
Compare:TSE:6869, NYSE:DGX, NYSE:LH, XPAR:ERF, SZSE:300676, XPAR:BIM, NYSE:PKI, NAS:QGEN, NYSE:Q, NYSE:BIO, XTER:SRT3, NYSE:A, NAS:ICLR, NAS:DXCM, NAS:EXAS, NAS:INCR, NYSE:CRL, MIL:DIA, NAS:PRAH, NAS:BRKR » details
Traded in other countries:IDXX.Austria, IX1.Germany,
Headquarter Location:USA
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 42% of its revenue from outside the United States.

Guru Investment Theses on IDEXX Laboratories Inc

Ron Baron Comments on IDEXX Laboratories - Apr 25, 2017

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) rose in the first quarter, rallying on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We think that IDEXX’s direct go-to-market model coupled with meaningful research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg)

From Ron Baron (Trades, Portfolio)'s first quarter 2017 Baron Partners Fund commentary.

Check out Ron Baron latest stock trades

Ron Baron Comments on IDEXX Laboratories Inc. - Nov 14, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased in the third quarter. The stock continued to rally on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We believe that IDEXX’s direct go-to-market model coupled with research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg)



From Ron Baron (Trades, Portfolio)'s Barons Partners Fund third-quarter 2016 commentary.

Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Oct 21, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased after the company reported impressive financial results, which led to a meaningful expansion in its trading multiple. We believe the company’s competitive position is strong and improving, as evidenced by its accelerating organic revenue growth, the robust placements of its diagnostic instruments into veterinary clinics, and the higher prices it is capturing across its product portfolio. In addition, IDEXX’s results demonstrated operating margin expansion, which is finally being recognized after several years of intensive investment into its business. Looking forward, we expect to witness sustained double-digit organic revenue growth during the next several years, driven by productivity benefits from its move to a direct sales model in the U.S., the company’s persistent innovation pipeline, and returns on its intensive investment into international markets.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Oct 11, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the leading provider of diagnostics to the veterinary industry. The company spends six times more on R&D annually than all its competitors combined. As a result, it has continuously improved its menu of diagnostics, which we believe is unsurpassed in the industry. IDEXX is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. The company’s products are sold via a razor/razorblade model, which produces high retention rates and incremental margins. We think that IDEXX’s direct go-to-market model coupled with meaningful R&D-driven product enhancements will continue to boost revenue and earnings growth over time.



From Baron Funds' fall 2016 newsletter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Aug 17, 2016

IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders.





From Baron Funds' Small Cap Fund second quarter 2016 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jul 25, 2016

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Ruane Cunniff Comments on Idexx Laboratories - Jul 13, 2016

We made the difficult decision during the quarter to part with our longtime holding in Idexx Laboratories (NASDAQ:IDXX). Idexx had been a wonderful stock for us over the past 13 years, compounding at better than a 17% rate from the time of our original purchases in 2003 through June 30. This compares to a 7.4% compound for the S&P 500 Index over the same period. Idexx has a terrific market position in veterinary diagnostics and a very capable CEO in Jon Ayers. But the market fully realizes Idexx’s strengths. It is according Idexx a price-to- earnings ratio of more than 40x the 2016 consensus earnings per share estimate of $ 2.21. The company has grown earnings per share at an 11% rate for the past five years and should grow a bit below that rate in 2016. The market helped with our decision as the price of Idexx shares rose sharply during the quarter. We owe a huge debt of gratitude to Jon Ayers. He is a hero to Sequoia shareholders and greatly respected by all of us.



From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Apr 26, 2016

Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jan 14, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Nov 04, 2015

Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg)



From Baron Funds' Baron Partners Fund shareholder letter for Q3 2015.



Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

IDEXX Laboratories to Release 2017 Third Quarter Financial Results
IDEXX Laboratories to Present at Bank of America Merrill Lynch Global Healthcare Conference
Brian McKeon Joins athenahealth Board of Directors
IDEXX Laboratories to Host 2017 Investor Day
IDEXX Laboratories Elects Stuart M. Essig to Board of Directors
Well-Managed, Competitively Advantaged Growth Companies Wanted Ron Baron has a system that IDs high-potential growth companies with fundamental analysis, intense focus on management and valuation models
Ron Baron (Trades, Portfolio) got his first taste of investing profits as a teenager. That was apparently enough to get him into the investment management industry and later to launch his own firm in 1982. Read more...
IDEXX Laboratories to Release 2017 Second Quarter Financial Results
IDEXX Laboratories to Present at William Blair Growth Stock Conference
IDEXX Laboratories Announces Increase in Share Repurchase Program
Ron Baron Comments on IDEXX Laboratories Guru stock highlight
Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) rose in the first quarter, rallying on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We think that IDEXX’s direct go-to-market model coupled with meaningful research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg) Read more...

Ratios

vs
industry
vs
history
PE Ratio 56.03
IDXX's PE Ratio is ranked lower than
76% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. IDXX: 56.03 )
Ranked among companies with meaningful PE Ratio only.
IDXX' s PE Ratio Range Over the Past 10 Years
Min: 15.18  Med: 31.2 Max: 62.12
Current: 56.03
15.18
62.12
Forward PE Ratio 45.25
IDXX's Forward PE Ratio is ranked lower than
88% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. IDXX: 45.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 56.03
IDXX's PE Ratio without NRI is ranked lower than
76% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. IDXX: 56.03 )
Ranked among companies with meaningful PE Ratio without NRI only.
IDXX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.02  Med: 30.97 Max: 62.12
Current: 56.03
15.02
62.12
Price-to-Owner-Earnings 59.97
IDXX's Price-to-Owner-Earnings is ranked lower than
68% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. IDXX: 59.97 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IDXX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.36  Med: 35.64 Max: 73.8
Current: 59.97
21.36
73.8
PS Ratio 7.91
IDXX's PS Ratio is ranked lower than
70% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. IDXX: 7.91 )
Ranked among companies with meaningful PS Ratio only.
IDXX' s PS Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.04 Max: 8.35
Current: 7.91
1.75
8.35
Price-to-Free-Cash-Flow 54.12
IDXX's Price-to-Free-Cash-Flow is ranked lower than
77% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. IDXX: 54.12 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IDXX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.01  Med: 34.27 Max: 84.69
Current: 54.12
13.01
84.69
Price-to-Operating-Cash-Flow 43.62
IDXX's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. IDXX: 43.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IDXX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.4  Med: 24.78 Max: 45.44
Current: 43.62
11.4
45.44
EV-to-EBIT 38.63
IDXX's EV-to-EBIT is ranked lower than
69% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. IDXX: 38.63 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 21.5 Max: 42.8
Current: 38.63
10.5
42.8
EV-to-EBITDA 32.01
IDXX's EV-to-EBITDA is ranked lower than
72% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. IDXX: 32.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.5 Max: 35.3
Current: 32.01
8.3
35.3
EV-to-Revenue 8.12
IDXX's EV-to-Revenue is ranked lower than
67% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. IDXX: 8.12 )
Ranked among companies with meaningful EV-to-Revenue only.
IDXX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 4 Max: 8.8
Current: 8.12
1.8
8.8
PEG Ratio 4.21
IDXX's PEG Ratio is ranked lower than
65% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. IDXX: 4.21 )
Ranked among companies with meaningful PEG Ratio only.
IDXX' s PEG Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.19 Max: 4.7
Current: 4.21
0.77
4.7
Shiller PE Ratio 94.46
IDXX's Shiller PE Ratio is ranked lower than
83% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. IDXX: 94.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
IDXX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.11  Med: 51.2 Max: 102.9
Current: 94.46
26.11
102.9
Current Ratio 0.92
IDXX's Current Ratio is ranked lower than
90% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. IDXX: 0.92 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 3.05 Max: 8.34
Current: 0.92
0.9
8.34
Quick Ratio 0.75
IDXX's Quick Ratio is ranked lower than
90% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IDXX: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.09 Max: 7.55
Current: 0.75
0.71
7.55
Days Inventory 74.78
IDXX's Days Inventory is ranked higher than
53% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. IDXX: 74.78 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 77.45  Med: 81.19 Max: 89.55
Current: 74.78
77.45
89.55
Days Sales Outstanding 47.09
IDXX's Days Sales Outstanding is ranked higher than
72% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. IDXX: 47.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 41.31 Max: 42.91
Current: 47.09
37.43
42.91
Days Payable 25.96
IDXX's Days Payable is ranked lower than
83% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. IDXX: 25.96 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.5 Max: 27.4
Current: 25.96
13.82
27.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.10
IDXX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. IDXX: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDXX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.4  Med: 2.2 Max: 6.2
Current: 5.1
-21.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.51
IDXX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
76% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. IDXX: 5.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IDXX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.49  Med: 2.6 Max: 26.47
Current: 5.51
1.49
26.47
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.08
IDXX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
67% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. IDXX: 3.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
IDXX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.06  Med: 2.26 Max: 3.75
Current: 3.08
1.06
3.75
Price-to-Median-PS-Value 1.96
IDXX's Price-to-Median-PS-Value is ranked lower than
85% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. IDXX: 1.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IDXX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 0.91 Max: 2.13
Current: 1.96
0.44
2.13
Price-to-Peter-Lynch-Fair-Value 4.00
IDXX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
76% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. IDXX: 4.00 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IDXX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.78  Med: 1.91 Max: 4.48
Current: 4
0.78
4.48
Earnings Yield (Greenblatt) % 2.59
IDXX's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. IDXX: 2.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IDXX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.3  Med: 4.7 Max: 9.5
Current: 2.59
2.3
9.5
Forward Rate of Return (Yacktman) % 15.21
IDXX's Forward Rate of Return (Yacktman) % is ranked higher than
72% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. IDXX: 15.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IDXX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.9  Med: 16.3 Max: 22.4
Current: 15.21
12.9
22.4

More Statistics

Revenue (TTM) (Mil) $1,862.27
EPS (TTM) $ 2.91
Beta0.42
Short Percentage of Float2.75%
52-Week Range $102.45 - 173.01
Shares Outstanding (Mil)87.28

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,952 2,126 2,331
EPS ($) 3.12 3.57 4.26
EPS without NRI ($) 3.12 3.57 4.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.73%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}